CN106511896A - Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine - Google Patents
Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine Download PDFInfo
- Publication number
- CN106511896A CN106511896A CN201611065898.6A CN201611065898A CN106511896A CN 106511896 A CN106511896 A CN 106511896A CN 201611065898 A CN201611065898 A CN 201611065898A CN 106511896 A CN106511896 A CN 106511896A
- Authority
- CN
- China
- Prior art keywords
- parts
- cerebral hemorrhage
- medicine
- medication
- convalescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 115
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 84
- 241000405414 Rehmannia Species 0.000 claims abstract description 18
- 208000034657 Convalescence Diseases 0.000 claims description 65
- 239000000843 powder Substances 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 23
- 241000237502 Ostreidae Species 0.000 claims description 22
- 235000020636 oyster Nutrition 0.000 claims description 22
- 240000009138 Curcuma zedoaria Species 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241000219784 Sophora Species 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 claims description 11
- 235000008113 selfheal Nutrition 0.000 claims description 11
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 241000427159 Achyranthes Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 244000179560 Prunella vulgaris Species 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 241001415959 Grus japonensis Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 210000004185 liver Anatomy 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 8
- 208000006011 Stroke Diseases 0.000 abstract description 8
- 230000001914 calming effect Effects 0.000 abstract description 8
- 208000032843 Hemorrhage Diseases 0.000 abstract description 6
- 238000001816 cooling Methods 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000002008 hemorrhagic effect Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 206010018852 Haematoma Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000008407 joint function Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 235000005881 Calendula officinalis Nutrition 0.000 abstract 1
- 240000001432 Calendula officinalis Species 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000011977 language disease Diseases 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 14
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 13
- 235000019509 white turmeric Nutrition 0.000 description 13
- 235000014375 Curcuma Nutrition 0.000 description 12
- 244000164480 Curcuma aromatica Species 0.000 description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 12
- 230000023597 hemostasis Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 102000005686 Serum Globulins Human genes 0.000 description 9
- 108010045362 Serum Globulins Proteins 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 241000721047 Danaus plexippus Species 0.000 description 8
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 244000307697 Agrimonia eupatoria Species 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 235000000125 common agrimony Nutrition 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 241000305492 Gastrodia Species 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001529739 Prunella <angiosperm> Species 0.000 description 5
- 206010046788 Uterine haemorrhage Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 241001480037 Microsporum Species 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 235000005412 red sage Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229930193974 gastrodin Natural products 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000009270 zilongjin Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000037488 Coccoloba pubescens Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241001516470 Cypripedium acaule Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000143510 Haliotis discus hannai Species 0.000 description 1
- 241001489138 Haliotis diversicolor Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000123747 Uncaria hirsuta Species 0.000 description 1
- 241000214513 Uncaria sinensis Species 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052595 hematite Inorganic materials 0.000 description 1
- 239000011019 hematite Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000011050 natural pearl Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine for a cerebral hemorrhage convalescent stage and a preparation method of the medicine. The medicine is prepared from the following components in parts by weight: 50-150 parts of concha haliotidis, 100-200 parts of ruddle, 20-80 parts of fossil fragments, 20-80 parts of concha ostreae, 20-80 parts of rhizoma gastrodiae, 25-125 parts of ramulus uncariae cum uncis, 50-110 parts of dried rehmannia root, 20-60 parts of cornus officinalis, 20-60 parts of rhizoma curcumae, 20-60 parts of flos sophorae and 20-60 parts of spica prunellae. The medicine has functions of calming liver and relieving endogenous wind, nourishing yin and suppressing yang, clearing heat and inducing diuresis, cooling blood and stopping bleeding, promoting blood circulation and removing stasis; and the medicine has a good treatment effect on disturbance of consciousness, language disorders as well as limb and joint function disorder of a patient with cerebral hemorrhage. In addition, the medicine has functions of stopping bleeding and promoting hematoma absorption. The medicine has a significant curative effect on acute hemorrhagic apoplexy and nerve function rehabilitation after the apoplexy. The medicine as an effective and effective Chinese patent medicine for treating the hemorrhagic apoplexy through oral administration, is free from toxic and side effects and adverse reactions to human body and is safe and efficient.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, in particular to a kind of cerebral hemorrhage convalescence medication and preparation method thereof.
Background technology
There is the convalescence of long period after cerebral hemorrhage, cerebral hemorrhage sequelae, the sequelae stayed after referring to cerebral hemorrhage, specifically
Show as hemiplegia, facial paralysis, slurred speech, hemianesthesia, dizziness, headache, flushing, bitter taste；Gently, moderate hemorrhagic brain
Angiosis is shown in above-mentioned shower.At present, for such illness can only be rested, the recovery that suitable medicine helps patient is had no, it is past
It is bad toward causing patient to recover slow, recovery effects.
In view of this, it is special to propose the present invention.
The content of the invention
The first object of the present invention is to provide a kind of cerebral hemorrhage convalescence medication, not suitable in prior art to solve
Close for the convalescent medicine of cerebral hemorrhage, cause apoplexy or post operation of hypertensive cerebral hemorrhage to recover slow, described cerebral hemorrhage convalescence medication, tool
There are nourishing and suppressing Yang, calming the liver to stop the wind, removing blood stasis and hemostasis.Can be used for apoplexy caused by liver yang causing wind, brain arteries and veins stasis blocking.
The second object of the present invention is to provide a kind of preparation method of described cerebral hemorrhage convalescence medication, and the method will
Medicine is respectively crushed into the meal and fine powder of different-grain diameter, and meal is decocted after merging, concentration, and is pelletized after mixing with fine powder, should
It is convenient, simple, easily operated that method has the advantages that, is adapted to batch production and extensively application, and can be according to the spy of Chinese medicine
Point makes drug effect fully discharge.
In order to realize the above-mentioned purpose of the present invention, spy employs the following technical solutions：
A kind of cerebral hemorrhage convalescence medication, including the following component prepared according to parts by weight：
50～150 parts of the shell of seaear, 100～200 parts of raddle, 20～80 parts of keel, 20～80 parts of oyster, rhizoma Gastrodiae 20～80
Part, 25～125 parts of yncaria stem with hooks, 50～110 parts of the dried rhizome of rehmannia, 20～60 parts of Fructus Corni, 20～60 parts of curcuma zedoary, 20～60 parts of sophora flower are withered with the summer
20～60 parts of grass.
The shell of seaear, is the shell of Bao Ke animal Haliotis diversicolors, haliotis discus hannai Ino, ear Bao, sheep Bao etc..Also known as natural pearls mother, abalone first,
Nine hole spiral shells, climbing groundsel, very sea certainly, extra large Cassia, CONCHA HALIOTIDI, abalone shells, the nine hole shells of seaear, abalone skin, golden clam skin.The shell of seaear has
Calming liver and clearing heat, effect of shade removing.Taste is salty；It is cold in nature.Main calcium carbonate. also containing organic matter and a small amount of magnesium, iron, silicic acid
The iodine of salt, sulfate, phosphate, chloride and denier. carbonate decomposition after calcining, calcium oxide is produced, organic matter is then broken
It is bad.
Raddle, is oxidation category corundum race mineral hematite ore.With calming the liver, important city drop is inverse, cooling blood and hemostasis it
Effect.Bitter, sweet, cold nature.Return liver, stomach, the heart channel of Hang-Shaoyin.For treating headache, dizziness, palpitaition are demented, frightened epilepsy, vomiting, gas,
Hiccup, dysphagic, cough, asthma are spitted blood, and nosebleed epistaxis, uterine bleeding are had blood in stool, hematuria.
Keel, another name：Lu Hu loses life, that gal bone, Os Draconis, calcined Dragon's bone, five OS DRACONISs, green grass or young cropsization keel, OS DRACONIS, Bai Long
Bone.Nature and flavor：It is sweet puckery, put down.Enter the heart, liver, kidney, large intestine channel.With transquilization with heavy material tranquillizing the mind by relieving convulsion, arrest sweating controlling nocturnal emission with astringent drugs, stop blooding puckery intestines, myogenic
Effect of sore.Cure mainly that frightened epilepsy is demented, palpitation is forgetful, insomnia and dreamful sleep, spontaneous sweating, stranguria with turbid discharge of passing out semen, tell nosebleed have blood in stool, uterine bleeding band
Under, rush down dysentery prolapse of the anus, ulcer do not closed up long.
Oyster, another name：Oyster clam, Gu Ben, left Gu oyster, male clam, oyster room, mountain, Pu, left housing, shell, oyster shell,
Oyster skin.Return liver and kidney channel.With calming the liver, transquilization with heavy material, softening and resolving hard mass, restrain astringent or styptic treatment for spontaneous sweating effect.Can be used for treatment
Dizziness and tinnitus, insomnia of palpitating with fear, scrofula goiter and tumor, abdominal mass lump in the abdomen, spontaneous sweating, seminal emission, uterine bleeding, under band.Contain what is enriched in medicine
Glycogen, taurine and various this essential amino acid of people, also rich in vitamin A, B1, B2, D, E, copper, zinc, manganese, barium, phosphorus, calcium etc.
Composition.
Rhizoma Gastrodiae, also known as rhizoma gastrodiae, solely shake sesame, from it is female, close from grass, refreshing grass, yellow moccasin flower, Mokpo, RHIZONA GASTRODIAE, DINGFENGCAO, Bai Long
Skin etc., is orchid family Gastrodia herbaceos perennial.Nature and flavor：It is sweet, put down.Enter Liver Channel.There is ceases wind, arresting convulsion.Control dizziness
Pupil, head wind headache, extremity numbness, hemiplegia, aphasia, pediatric epilepsy scared move wind.Rhizoma Gastrodiae is more rich in Gastrodin, rhizoma Gastrodiae
Sugar, vitamin A, glucoside, alkaloid, vanillyl alcohol, vanillin, butanedioic acid, cupreol, lymphatic temperament etc., wherein Gastrodin
It is main component with gastrodia elata polysaccharide.
Yncaria stem with hooks, is that madder wort yncaria stem with hooks, largeleaf gambirplant branchlet, uncaria hirsuta, Uncaria sinensis or stockless fruit yncaria stem with hooks are dried buckle stem
Branch.The effect of with dispelling wind and relieving convulsion, The flat liver of heat-clearing.It is sweet, it is cool in nature.Return liver, pericardium channel.With dispelling wind and relieving convulsion, The flat liver of heat-clearing
Effect.For treating liver wind agitation, twitch, hyperpyretic convulsion, dysphoric cold, children's crying with fear, pre-eclampsia, dizziness of having a headache.
The dried rhizome of rehmannia, calls radix rehmanniae recen, wild country Huang, mountain cigarette root etc..It is sweet, it is cold in nature.The thoughts of returning home, liver and kidney channel.Radix rehmanniae recen rhizome is main
Sitosterol containing B- and mannitol, and a small amount of stigmasterol, micro campesterol, also containing rehmanin, alkaloid, aliphatic acid, Catalpol,
Glucose and 0.0053% retinoid material；Root contains stachyose, 4.2% arginine and 3.0% γ-Gamma Amino Butyric Acid again.Bosom celebrating
The rhizome of glutinous rehmannia also contains mannitol, stachyose, 0.11% Catalpol, sucrose, 4.2% arginine, 3.0% γ-Gamma Amino Butyric Acid.Dry ground
Get a series of aliphatic acid, cupreol, palmitic acid, succinic acid, Daucosterol and S8 cyclic compounds in Huang.Glutinous rehmannia has
Anastalsis, has blood coagulation resisting function again.Additionally, glutinous rehmannia also has antifungic action, glutinous rehmannia flooding agent is to trichophyton mentagrophytes, gypsum sample
The growth of various fungies such as microsporum, ulotrichy microsporum and microsporum audouini has inhibitory action.
Fructus Corni, is the drying and ripening pulp of Cornaceae plant Fructus Corni.Taste is sour, puckery, slightly warm in nature.With help liver
The effect of kidney, arresting collape syndrome by astringents.Return liver and kidney channel.Have functions that to tonify the liver and kidney, arresting collape syndrome by astringents.For treating dizziness and tinnitus, waist and knee
Ache, impotence and seminal emission, enuresis frequent micturition, uterine bleeding under band, profuse sweating collapse, Heat Diabetes.
Curcuma zedoary, is the rhizome of zingiberaceous plant curcuma zedoary, Guangxi zedoary and RADIX CURCUMAE.Taste is pungent, hardship, it is warm in nature.Return liver, the spleen channel.Tool
There are promoting the circulation of qi blood-breaking, Xiao Ji Zhi Tong.For treating pained vim and vigour, eating accumulation, abdominal distention, amenorrhea due to stagnation of blood, dysmenorrhoea, disease
Lump in the abdomen knurl lump in the abdomen, traumatic injury.Curcuma zedoary has antitumor, Robust speaker feature, antibacterial, increasing leukocyte, liver protection, antiinflammatory action.In addition, cowherb
Art also plays the role of brilliance to cardiovascular and acute renal failure, it is important that can also suppress platelet aggregation and antithrombotic
Formed.
Sophora flower, is that legume Chinese scholartree is dried flower and alabastrum.Bitter, cold nature.Return liver, large intestine channel.With cooling blood and hemostasis,
Effect of clearing liver-fire.For treatment have blood in stool, hemorrhoid blood, bloody flux, uterine bleeding, haematemesis, bleeding from five sense organs or subcutaneous tissue, the hot hot eyes of liver, dizziness of having a headache.
Selfheal, taste is pungent, hardship are cold in nature.Return liver, gallbladder channel.There is clearing liver-fire, improving eyesight, mass dissipating and swelling eliminating.For controlling
Treat red eye, swell pain, mesh pearl nyctalgia, dizziness of having a headache, scrofula, goiter and tumor, acute mastitis, newborn addiction, swollen breasts.
To sum up, cerebral hemorrhage convalescence medication provided herein, all medicine compatibilities of the above, slow mark are anxious, and the void of amended copy,
Moreover relieve inflammation or internal heat i.e. so enriching yin, when this is urgent, the product of mistake enriching yin, renvoi mud diaphragm and hinder mechanism of qi, then manage from modern medicine
By speech, mostly the urgency person of apoplexy, cerebral hemorrhage type, the product of the important city clearing liver of we, intracranial pressure is advantageously reduced, promoting blood circulation and hemostasis are simultaneously
With can both prevent Continuous hemorrhage, the blood that gone out can be promoted to absorb again.Wherein, the shell of seaear and raddle are monarch drug in a prescription, are ceased with heat-clearing
Wind, softening hard masses are spun the antipyretic effect of inverse, cool blood by the stasis of blood, town, the two mutually and, treat both principal and secondary aspect of disease.And keel, oyster, rhizoma Gastrodiae and yncaria stem with hooks
For ministerial drug, keel and oyster are arranged in pairs or groups with monarch drug in a prescription, the effect with town liver checking exuberance of yang, and rhizoma Gastrodiae and yncaria stem with hooks are collocated with principal drug assistance with monarch drug in a prescription
Calm down the effect of latent wind-heat.Remaining Chinese medicine is adjutant, and wherein the dried rhizome of rehmannia and Fructus Corni have nourishing liver and kidney, positive cloudy keep not
Multiple upper effect more.And effect of the collocation with hemostasia and dissipation blood stasis of curcuma zedoary, sophora flower.With nourishing and suppressing Yang, calming the liver to stop the wind, removing blood stasis and hemostasis
Effect.
Preferably, described cerebral hemorrhage convalescence medication, including the following component prepared according to parts by weight：
70～130 parts of the shell of seaear, 120～180 parts of raddle, 30～70 parts of keel, 40～60 parts of oyster, rhizoma Gastrodiae 20～80
Part, 45～95 parts of yncaria stem with hooks, 70～90 parts of the dried rhizome of rehmannia, 30～50 parts of Fructus Corni, 30～50 parts of curcuma zedoary, 30～50 parts of sophora flower and selfheal
30～50 parts.
The component of above-mentioned cerebral hemorrhage convalescence medication can be carried out preferably.
Preferably, described cerebral hemorrhage convalescence medication, including the following component prepared according to parts by weight：
90～110 parts of the shell of seaear, 140～160 parts of raddle, 40～60 parts of keel, 45～55 parts of oyster, rhizoma Gastrodiae 40～60
Part, 60～80 parts of yncaria stem with hooks, 75～85 parts of the dried rhizome of rehmannia, 35～45 parts of Fructus Corni, 35～45 parts of curcuma zedoary, 35～45 parts of sophora flower and selfheal
35～45 parts.
The component of above-mentioned cerebral hemorrhage convalescence medication can be carried out further preferably.
Preferably, described cerebral hemorrhage convalescence medication, in terms of parts by weight, also includes：20～40 parts of the root of bidentate achyranthes.
It is root of bidentate achyranthes bitter, sweet, sour, it is mild-natured.Return liver and kidney channel.With dispelling stasis of blood and stimulating the menstrual flow, filling liver kidney, strengthening the bones and muscles, inducing diuresis for treating strangurtia, draw
The descending effect of blood.For treating Amenorrhea, dysmenorrhoea, soreness of waist and knee joint, powerless muscles and bones, stranguria, oedema, headache, dizziness, toothache, day
The diseases such as sore, haematemesis, bleeding from five sense organs or subcutaneous tissue.And the root of bidentate achyranthes is in cerebral hemorrhage convalescence medication provided herein, collocation monarch drug in a prescription has and draws under blood
Capable effect.
Preferably, described cerebral hemorrhage convalescence medication, in terms of parts by weight, also includes：20～40 parts of rhizoma alismatis.
Rhizoma alismatis, is the dry tuber of Notes On Alism At Aceae rhizoma alismatis.It is sweet, light, it is cold in nature.Return kidney, bladder warp.Ooze with Li Shui
Effect that is wet, expelling the heat-evil, change turbid lipid-loweringing.There is inducing diuresis for removing edema, strengthen tonifying yin with monarch drug in a prescription collocation.
Preferably, described cerebral hemorrhage convalescence medication, in terms of parts by weight, also includes：40～60 parts of hairyvein agrimony.
Hairyvein agrimony is mild-natured, bitter, puckery.There is hemostasis, cardiac stimulant, antibacterial, expelling parasite.Take with curcuma zedoary in adjutant and sophora flower
Match somebody with somebody, with more preferable cooling blood and hemostasis, effect promoting blood circulation and removing blood stasis.
The preparation method of cerebral hemorrhage convalescence medication as above, comprises the following steps：
(1), curcuma zedoary, yncaria stem with hooks are crushed, are sieved, obtain powder standby；
(2), the shell of seaear, keel, oyster, raddle are crushed and is sieved, mixed with remaining Chinese medicine and added water and be pan-fried
Boil, the dregs of a decoction are decocted by filtering liquid medicine again, filter and merge liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, thick paste is obtained, and with step (1) in powder
With appropriate dextrin mixing, granulation, be dried, crush after, add ethanol in proper amount, granulation, be dried, obtain the cerebral hemorrhage convalescence use
Medicine；
Preferably, the relative density of the thick paste is 1.30-1.35 (80 DEG C).
Medicine is respectively crushed into the thick of different-grain diameter by the preparation method of cerebral hemorrhage convalescence medication provided herein
Powder and fine powder, meal merge other decocting for Chinese herbal medicine, concentration, and pelletize after mixing with fine powder, and the method has conveniently, simply, easily
The advantages of operation, it is adapted to batch production and extensively application, and according to the characteristics of Chinese medicine drug effect can be made fully to discharge.
Preferably, the preparation method of described cerebral hemorrhage convalescence medication, it is in step (1), described to sieve specially
60～100 mesh sieve.
Powder in step (1) is thin, particle diameter is little, therefore crosses 60～100 mesh sieve.
Preferably, in step (2), it is described sieve specially 4～40 mesh sieve.
In step (2), crushing is that, for the ease of decocting medicinal herbs, it is meticulous that powder is difficult, therefore crosses 4～40 mesh sieve.
Preferably, in step (2), the time of the decoction is 1.5～2 hours, and the time for decocting again is 1.5
～2 hours.
Compared with prior art, beneficial effects of the present invention are：
1) a kind of, cerebral hemorrhage convalescence medication provided herein, the shell of seaear and raddle are monarch drug in a prescription, are ceased with heat-clearing
Wind, softening hard masses are spun the antipyretic effect of inverse, cool blood by the stasis of blood, town, the two mutually and, treat both principal and secondary aspect of disease.And keel, oyster, rhizoma Gastrodiae and yncaria stem with hooks
For ministerial drug, keel and oyster are arranged in pairs or groups with monarch drug in a prescription, the effect with town liver checking exuberance of yang, and rhizoma Gastrodiae and yncaria stem with hooks are collocated with principal drug assistance with monarch drug in a prescription
The effect of latent wind-heat is calmed down, remaining is adjutant.
2), a kind of cerebral hemorrhage convalescence medication provided herein, with nourishing and suppressing Yang, calming the liver to stop the wind, removing blood stasis and hemostasis
Effect.Wherein, hairyvein agrimony and curcuma zedoary in adjutant and sophora flower collocation, with more preferable cooling blood and hemostasis, effect promoting blood circulation and removing blood stasis.
3) medicine is respectively crushed into by a kind of, preparation method of cerebral hemorrhage convalescence medication provided herein, the method
The meal and fine powder of different-grain diameter, meal is decocted after merging, concentration, and is pelletized after mixing with fine powder, convenient, letter that the method has
Single, easily operated the advantages of, it is adapted to batch production and extensively application, and according to the characteristics of Chinese medicine drug effect can be made fully to release
Put.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.It is unreceipted concrete in embodiment
Condition person, the condition advised according to normal condition or manufacturer are carried out.Agents useful for same or the unreceipted production firm person of instrument, are
The conventional products that commercially available purchase is obtained can be passed through.
Embodiment 1
The cerebral hemorrhage convalescence medication provided by the present embodiment is prepared from using following methods：
(1), 20g curcuma zedoarys, 25g yncaria stems with hooks are crushed, cross 60 mesh sieves, obtain fine powder standby；
(2), the 50g shells of seaear, 100g keel, 20g oysters, 100g raddles are crushed and crosses 4 mesh sieves and obtain meal, meal
Mixed with 20g rhizoma Gastrodiaes, the 50g dried rhizome of rehmannia, 20g Fructus Cornis, 20g sophoras flower and 20g selfheals and added water to cook 2 hours, filtered medicine
Liquid, the dregs of a decoction is decocted again 1.5 hours, after filtration and merges liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, it is 1.30 (80 DEG C) thick paste to obtain relative density,
And after mixing, pelletize, being dried with fine powder and appropriate dextrin in step (1), crushing, add ethanol in proper amount, granulation, it is dried,
Obtain cerebral hemorrhage convalescence medication.
Embodiment 2
The cerebral hemorrhage convalescence medication provided by the present embodiment is prepared from using following methods：
(1), 60g curcuma zedoarys, 125g yncaria stems with hooks are crushed, cross 100 mesh sieves, obtain fine powder standby；
(2), the 150g shells of seaear, 80g keel, 80g oysters, 200g raddles are crushed and crosses 10 mesh sieves and obtain meal, slightly
Powder is entered with 80g rhizoma Gastrodiaes, the 110g dried rhizome of rehmannia, 60g Fructus Cornis, 60g sophoras flower, 60g selfheals, the 40g roots of bidentate achyranthes, 40g rhizoma alismatis and 60g hairyvein agrimonies
Row mixing is simultaneously added water to cook 1.5 hours, filtering liquid medicine, the dregs of a decoction is decocted again 2 hours, after filtration and merging liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, it is 1.35 (80 DEG C) thick paste to obtain relative density,
And after mixing, pelletize, being dried with fine powder and appropriate dextrin in step (1), crushing, add ethanol in proper amount, granulation, it is dried,
Obtain cerebral hemorrhage convalescence medication.
Embodiment 3
The cerebral hemorrhage convalescence medication provided by the present embodiment is prepared from using following methods：
(1), 30g curcuma zedoarys, 45g yncaria stems with hooks are crushed, cross 80 mesh sieves, obtain fine powder standby；
(2), the 70g shells of seaear, 30g keel, 40g oysters, 120g raddles are crushed and crosses 20 mesh sieves and obtain meal, meal
Carry out with 20g rhizoma Gastrodiaes, the 70g dried rhizome of rehmannia, 30g Fructus Cornis, 30g sophoras flower, 30g selfheals, the 20g roots of bidentate achyranthes, 20g rhizoma alismatis and 40g hairyvein agrimonies
Mix and add water to cook 2 hours, the dregs of a decoction are decocted 1.5 hours by filtering liquid medicine again, after filtration and merge liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, it is 1.31 (80 DEG C) thick paste to obtain relative density,
And after mixing, pelletize, being dried with fine powder and appropriate dextrin in step (1), crushing, add ethanol in proper amount, granulation, it is dried,
Obtain cerebral hemorrhage convalescence medication.
Embodiment 4
The cerebral hemorrhage convalescence medication provided by the present embodiment is prepared from using following methods：
(1), 50g curcuma zedoarys, 95g yncaria stems with hooks are crushed, cross 100 mesh sieves, obtain fine powder standby；
(2), the 130g shells of seaear, 70g keel, 60g oysters, 180g raddles are crushed and crosses 30 mesh sieves and obtain meal, slightly
Powder is entered with 80g rhizoma Gastrodiaes, the 90g dried rhizome of rehmannia, 50g Fructus Cornis, 50g sophoras flower, 50g selfheals, the 30g roots of bidentate achyranthes, 30g rhizoma alismatis and 50g hairyvein agrimonies
Row mixing is simultaneously added water to cook 2 hours, filtering liquid medicine, the dregs of a decoction is decocted again 1.5 hours, after filtration and merging liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, it is 1.32 (80 DEG C) thick paste to obtain relative density,
And after mixing, pelletize, being dried with fine powder and appropriate dextrin in step (1), crushing, add ethanol in proper amount, granulation, it is dried,
Obtain cerebral hemorrhage convalescence medication.
Embodiment 5
The cerebral hemorrhage convalescence medication provided by the present embodiment is prepared from using following methods：
(1), 40g curcuma zedoarys, 75g yncaria stems with hooks are crushed, cross 100 mesh sieves, obtain fine powder standby；
(2), the 100g shells of seaear, 50g keel, 50g oysters, 150g raddles are crushed and crosses 40 mesh sieves and obtain meal, slightly
Powder is entered with 50g rhizoma Gastrodiaes, the 80g dried rhizome of rehmannia, 40g Fructus Cornis, 40g sophoras flower, 40g selfheals, the 30g roots of bidentate achyranthes, 30g rhizoma alismatis and 40g hairyvein agrimonies
Row mixing is simultaneously added water to cook 2 hours, filtering liquid medicine, the dregs of a decoction is decocted again 1.5 hours, after filtration and merging liquid twice；
(3), the liquid twice after merging in step (2) is concentrated, it is 1.35 (80 DEG C) thick paste to obtain relative density,
And after mixing, pelletize, being dried with fine powder and appropriate dextrin in step (1), crushing, add ethanol in proper amount, granulation, it is dried,
Obtain cerebral hemorrhage convalescence medication.
1 stability experiment of experimental example
The proterties of the cerebral hemorrhage convalescence medication for respectively the embodiment of the present application 1～5 being provided at normal temperatures, discriminating, inspection
Look into, the project such as assay, health examination is checked that every Index for examination is qualified at the appointed time, illustrates stone
Imperial Qingxue Granules have certain stability.
2 toxicologic study of experimental example
(1) the cerebral hemorrhage convalescence medication provided to the embodiment of the present application 1～5 by acute toxicity testing carries out acute toxicity
Experiment, animal ICR kinds and Kunming kind male and female mouse, 20～21 grams of body weight, 80 male and female half and half, purchased from the Chinese Academy of Medical Sciences
Institute of lab animals's breeding field.
The electuary patent medicine 20g/kg (Cmaxs of the cerebral hemorrhage convalescence medication provided by oral the embodiment of the present application 5
0.5g/ml) with maximum volume (0.4ml/10g), 10g/kg and 3g/kg, the female male mice of male and female ICR mouse and Kunming do not go out
Existing toxic reaction and death.Table 1 is the Continuous Observation toxicity test result of 7 days.
1 acute toxicity test in mice result of table
(2) long term toxicity test
The cerebral hemorrhage convalescence medication provided by heavy dose of oral application embodiment 5, Cmax (0.5g/ml),
1.5ml/100g, 15g/kg, by daily single, are administered 67 days altogether, do not cause the exception of the experimental index such as the heart, liver, lung, kidney
Change, it was demonstrated that stone dragon Qingxue Granules toxicity is extremely low, and degree of safety is high.
3 pharmacodynamic study of experimental example
The cerebral hemorrhage convalescence medication provided by the embodiment of the present application 1,3,5, with regard to carrying out pharmacodynamics reality in terms of following four
Test：
(1) impact to blood plasma euglobulin lysis time；
(2) impact to plasma fibrinogen content；
(3) Platelet is affected；
(4) impact to blood plasma recalcification time.
(1) experiment material
1.1 animal
Wistar rats, male, 195～215g of body weight, purchased from Chinese Academy of Medical Sciences's Institute of Botany animal feeding field.
1.2 medicine
Embodiment：Cerebral hemorrhage convalescence medication the embodiment of the present application 1～5 that the embodiment of the present application 1,3,5 is provided is carried
For cerebral hemorrhage convalescence medication, be brown-red powder, during experiment with 1% starch suspension prepare；
Comparative example 1：Aspirin, commercially available product are made into suspension with 1% starch；
Comparative example 2：Red sage root aqua, is prepared by institute of Materia Medica,Chinese Academy of Medical Sciences, and supernatant use is taken after centrifugation；
Fibrinogen：Ministry of Public Health institute for drug control provides.
Collagen liquid：One fritter of rat abdomen skin is taken, is shredded, add 1ml physiological saline to make homogenate per 100ml, with
2500rpm is centrifuged 5 minutes, application liquid of the Aspirate supernatant as collagen.
Adenosine diphosphate (ADP) (ADP)：SIGMA factories produce.
Other reagents are commercially available product, analyze pure.
1.3 instrument
72 type spectrophotometers：The 3rd instrument plant of Shanghai；
Four lead automatic platelet aggregation instrument：PAT 4A4M types, Japan's system；
Nx-2 Blood coagulation instruments：Shanghai Kodak tester factory.
(2) experimental technique and result
Rat 50 is only randomly divided into into 5 groups, 10 per group：Control group, embodiment group (embodiment 1,3,5 be respectively 2,4,
8g/kg) and aspirin group (0.025g/kg).Gastric infusion (10ml/kg), control group is taken to give and wait capacity water.Except Ah Si
Woods group is outer by daily single, and remaining organizes daily gavage twice, equal successive administration 14.5 days (being shown in Table 2).After last dose, 1 is little
When press 40mg/kg intraperitoneal injection of anesthesia medicines with 2% yellow Jackets.With silication syringe from abdominal aortic blood, survey respectively
Determine blood plasma euglobulin lysis time, plasma fibrin content (biuret method), Platelet (turbidimetry) and blood plasma
Recalcification time.
Rat 20 is only divided into into two groups：Control group and red sage root group, with yellow Jackets anesthetized animal in intravenous injection one
Secondary medicine (10g/kg) is waited 15 minutes after capacity physiological saline 5ml/kg, from abdominal aortic blood, determines blood plasma euglobulin
Dissolution time.
As shown in table 2, experimental result is by shown in table 3～7 for rat administrations.
2 rat of table is grouped and administrations
Impact experimental result of the table 3 to rat plasma euglobulin lysis time
From table 3, cerebral hemorrhage convalescence medication low dose (1g/kg, 2 times a day) provided herein is substantially shortened
Blood plasma euglobulin lysis time, as dosage increase effect strengthens, reacts in dosage effect.Brain provided herein goes out
Blood convalescence medication heavy dose (4g/kg, 2 times a day), can make blood plasma euglobulin lysis time shorten only about half of (P<
0.001) antiplatelet drug aspirin is had no significant effect to blood plasma euglobulin lysis time.After positive control drug red sage root intravenous
Blood plasma euglobulin lysis time substantially shortens (P<0.05).
Impact experimental result of the table 4 to rat plasma fibrinogen content
As shown in Table 4, imperial electuary daily 2g/kg and 4g/kg makes rat plasma fibrinogen content slightly reduce, dosage
Effect when increasing to daily 8g/kg slightly strengthens.3 dosage group P compared with control group<0.05 (being shown in Table 3).Antiplatelet drug Ah Si
Woods is had no significant effect to plasma fibrinogen content.
Impact experimental result of the table 5 to rat platelet aggregation
As shown in Table 5, taken after blood from rat aorta with 3.8% sodium citrate anti-freezing.Richness is prepared conventionally
Add 5% collagen solution, 10 μ L or ADP (250 μ g/ in 0.2mLPRP containing thrombocyte plasma (PRP) platelet poor plasma (PPP)
ml)10μL.Trace curve of platelet aggregation.Calculate to maximum platelet aggregation rate in after derivant 10 minutes and the 10th minute
Platelet disaggregation rate.
Impact experimental result of the table 6 to rat platelet disaggregation
As shown in Table 6, positive control drug aspirin significantly inhibits effect to collagen-induced platelet aggregation.This Shen
The cerebral hemorrhage convalescence medication for please being provided has the tendentiousness for suppressing aggregation.To ADP induced aggregations, aspirin has becoming for suppression
To cerebral hemorrhage convalescence medication provided herein is then without obvious effect.To the disaggregation after ADP induced platelet aggregations,
Aspirin has the facilitation of highly significant, significantly higher than disaggregation rate (51%), control group (12%).Middle dosage and big
The cerebral hemorrhage convalescence medication provided herein of dosage has obvious depolymerisation (P<0.01).Aspirin is to collagen
Disaggregation after induced platelet aggregation, has the tendentiousness for promoting depolymerization, and cerebral hemorrhage convalescence medication provided herein has
Certain depolymerisation, the more apparent (P of middle dosage<0.05).
Impact experimental result of the table 7 to rat plasma recalcification time
As shown in Table 7, cerebral hemorrhage convalescence medication middle dosage provided herein and heavy dose of group have shortening blood plasma multiple
The tendentiousness of calcium time, the shortening time compared with control group, less than 15%, no difference of science of statistics (P>0.05).
To sum up, cerebral hemorrhage convalescence medication provided herein can make rat plasma euglobulin lysis time substantially contract
Short, fibrinogen content declines, and shows that FA increases.Brain provided herein is not observed in this experiment
Bleeding convalescence medication has obvious inhibiting effect to rat platelet aggregation, the tendentiousness for only suppressing, and may lure with all
Lead that agent concentration is higher relevant, cerebral hemorrhage convalescence medication provided herein has to the depolymerization after ADP or collagen-induced aggregations
It is obviously promoted effect.Recalcification time reacts Clinical significant of coagulation function, and cerebral hemorrhage convalescence medication provided herein has promotion solidifying
The tendentiousness of blood.Clinical effective with cerebral hemorrhage convalescence medication treatment cerebral hemorrhage convalescence patient provided herein, which is controlled
Treat mechanism and may promote platelet disaggregation, so that posthemorrhagic hemotoncus prompt resolution is relevant with its reinforcing fiber activity.
Also, show through prolonged clinical observation result, cerebral hemorrhage convalescence medication provided herein has
Calming liver to stop endogenous wind, nourishing and suppressing Yang, clearing away heat and promoting diuresis, cooling blood and hemostasis, effect promoting blood circulation and removing blood stasis, for the consciousness of hemorrhagic stroke patient hinders
Hinder, aphasis, limb and joint function obstacle have good therapeutic action.And the effect with hemostasis, promotion absorption of hematoma.
For the neurological rehabilitation after Acute Hemorrhagic Apoplexy and apoplexy has obvious curative effect.To human body without toxicity, side effect and not
Good reaction, it is safe and efficient, it is the Chinese patent drug for oral administration for treating hemorrhagic stroke effectively, safe.
Although with specific embodiment illustrate and describing the present invention, but it will be appreciated that without departing substantially from the present invention's
Many other changes and modification can be made in the case of spirit and scope.It is, therefore, intended that in the following claims
Including all such changes and modifications belonged in the scope of the invention.
Claims (10)
1. a kind of cerebral hemorrhage convalescence medication, it is characterised in that include the following component prepared according to parts by weight：
50～150 parts of the shell of seaear, 100～200 parts of raddle, 20～80 parts of keel, 20～80 parts of oyster, 20～80 parts of rhizoma Gastrodiae,
25～125 parts of yncaria stem with hooks, 50～110 parts of the dried rhizome of rehmannia, 20～60 parts of Fructus Corni, 20～60 parts of curcuma zedoary, 20～60 parts of sophora flower and selfheal
20～60 parts.
2. cerebral hemorrhage convalescence medication according to claim 1, it is characterised in that include according to parts by weight prepare as
Lower component：
70～130 parts of the shell of seaear, 120～180 parts of raddle, 30～70 parts of keel, 40～60 parts of oyster, 20～80 parts of rhizoma Gastrodiae,
45～95 parts of yncaria stem with hooks, 70～90 parts of the dried rhizome of rehmannia, 30～50 parts of Fructus Corni, 30～50 parts of curcuma zedoary, 30～50 parts of sophora flower and selfheal 30
～50 parts.
3. cerebral hemorrhage convalescence medication according to claim 1, it is characterised in that include according to parts by weight prepare as
Lower component：
90～110 parts of the shell of seaear, 140～160 parts of raddle, 40～60 parts of keel, 45～55 parts of oyster, 40～60 parts of rhizoma Gastrodiae,
60～80 parts of yncaria stem with hooks, 75～85 parts of the dried rhizome of rehmannia, 35～45 parts of Fructus Corni, 35～45 parts of curcuma zedoary, 35～45 parts of sophora flower and selfheal 35
～45 parts.
4. the cerebral hemorrhage convalescence medication according to any one of claim 1-3, it is characterised in that in terms of parts by weight, also
Including：20～40 parts of the root of bidentate achyranthes.
5. cerebral hemorrhage convalescence medication according to claim 4, it is characterised in that in terms of parts by weight, also include：Rhizoma alismatis
20～40 parts.
6. cerebral hemorrhage convalescence medication according to claim 4, it is characterised in that in terms of parts by weight, also include：Red crowned crane
40～60 parts of grass.
7. the preparation method of the cerebral hemorrhage convalescence medication according to any one of claim 1-6, it is characterised in that include with
Lower step：
(1), curcuma zedoary, yncaria stem with hooks are crushed, are sieved, obtain powder standby；
(2), the shell of seaear, keel, oyster, raddle are crushed and is sieved, mixed and added water to cook with remaining Chinese medicine, mistake
Filter liquid, the dregs of a decoction are decocted again, liquid twice is filtered and merge；
(3), the liquid twice after merging in step (2) is concentrated, thick paste is obtained, and with step (1) in powder and fit
Amount dextrin mixing, granulation, be dried, crush after, add ethanol in proper amount, granulation, be dried, obtain cerebral hemorrhage convalescence medication；
Preferably, the relative density of the thick paste is 1.30-1.35 (80 DEG C).
8. the preparation method of cerebral hemorrhage convalescence medication according to claim 7, it is characterised in that in step (1), institute
State sieve specially 60～100 mesh sieve.
9. the preparation method of cerebral hemorrhage convalescence medication according to claim 7, it is characterised in that in step (2), institute
State sieve specially 4～40 mesh sieve.
10. the preparation method of cerebral hemorrhage convalescence medication according to claim 7, it is characterised in that in step (2),
The time of the decoction is 1.5～2 hours, and the time for decocting again is 1.5～2 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611065898.6A CN106511896A (en) | 2016-11-28 | 2016-11-28 | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611065898.6A CN106511896A (en) | 2016-11-28 | 2016-11-28 | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511896A true CN106511896A (en) | 2017-03-22 |
Family
ID=58357729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611065898.6A Pending CN106511896A (en) | 2016-11-28 | 2016-11-28 | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511896A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108543038A (en) * | 2018-07-06 | 2018-09-18 | 葵花药业集团（吉林）临江有限公司 | A kind of Chinese medicine composition of removing blood stasis and hemostasis and its preparation method and application |
-
2016
- 2016-11-28 CN CN201611065898.6A patent/CN106511896A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘媛媛等: "小剂量甘露醇联合石龙清血颗粒治疗高血压性脑出血的临床观察", 《中国药房》 * |
| 杨培民等: "《最新中成药手册》", 30 November 2014 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108543038A (en) * | 2018-07-06 | 2018-09-18 | 葵花药业集团（吉林）临江有限公司 | A kind of Chinese medicine composition of removing blood stasis and hemostasis and its preparation method and application |
| CN108543038B (en) * | 2018-07-06 | 2021-08-17 | 葵花药业集团（吉林）临江有限公司 | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN102772745A (en) | Chinese medicinal preparation for treating cancer and preparation method thereof | |
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN106421649A (en) | Traditional Chinese medicine composition for treating cerebral apoplexy and preparation method thereof | |
| CN104173773A (en) | Preparation with functions of treating migraine, dispelling wind and promoting blood circulation and preparation methods | |
| CN106994141B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN106511896A (en) | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine | |
| CN103638475A (en) | Traditional Chinese medicinal spray for treating lump in breast and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105435190A (en) | Traditional Chinese medicine composition for treating cold-heat jumble asthma and preparation method of traditional Chinese medicine composition | |
| CN104547494A (en) | Traditional Chinese medicine composition medicinal liquor for treating hyperthyroidism and preparation process | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN107837383A (en) | A kind of traditional Chinese powder medicine for treating cardiovascular and cerebrovascular diseases | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN107320665A (en) | Treat precocious pharmaceutical composition of child and preparation method thereof | |
| CN101391045B (en) | Traditional Chinese medicine compound preparation for treating migraine and general headache and preparation method thereof | |
| CN106692858A (en) | Medicine for treating threatened abortion and preparation method of medicine | |
| CN105832934A (en) | Traditional Chinese medicine for treating hypertension | |
| CN104162112B (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN104162038A (en) | Traditional Chinese medicine composition for treating neonatal seizures and preparation method thereof | |
| CN104383247A (en) | Traditional Chinese medicine for treating phthisis | |
| CN104258302A (en) | Traditional Chinese medicine for treating chronic idiopathic thrombocytopenic purpura due to fire excess from yin deficiency and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |